• No significant interaction was observed between treatment and obesity status (nonobese, obese/non-morbid, and morbidly obese) for recurrent VTE (interaction P = .170) and MB (interaction P = .674)
    • Regardless of obesity status, effects of apixaban versus those of warfarin on recurrent VTE and MB were consistent and showed lower rates for apixaban than for warfarin
  • One significant interaction was observed for CRNM bleeding (interaction P = .023)
    • While apixaban trended towards a lower risk of CRNM bleeding compared with warfarin across nonobese, obese/non-morbid, and morbidly obese patients, the magnitude of the difference was bigger for morbidly
      obese patients versus for the other 2 subgroups
  • Among obese and morbidly obese patients, patients on apixaban had a significantly lower risk of recurrent VTE,
    MB, and CRNM bleeding compared with warfarin patients